

Hong Kong Exchanges and Clearing Limited and the Stock Exchange take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from, or in reliance upon, the whole or any part of the contents of this announcement.



深圳市海王英特龍生物技術股份有限公司
SHENZHEN NEPTUNUS INTERLONG BIO-TECHNIQUE COMPANY LIMITED*
(a joint stock limited company incorporated in the People's Republic of China)
(Stock code: 8329)

**ABSTRACT OF THE FIRST QUARTERLY RESULTS
FOR THE THREE MONTHS ENDED 31 MARCH 2024**

**CHARACTERISTICS OF GEM OF THE STOCK EXCHANGE OF HONG KONG LIMITED
(THE “STOCK EXCHANGE”)**

GEM has been positioned as a market designed to accommodate small and mid-sized companies to which a higher investment risk may be attached than other companies listed on the Stock Exchange. Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration.

Given that the companies listed on GEM are generally small and mid-sized companies, there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board and no assurance is given that there will be a liquid market in the securities traded on GEM.

* For identification purpose only

The board (the “**Board**”) of Directors (the “**Directors**”) of Shenzhen Neptunus Interlong Bio-technique Company Limited (the “**Company**”) is pleased to present the unaudited abstract of results of the Company and its subsidiaries (collectively the “**Group**”) for the three months ended 31 March 2024, together with the unaudited comparative figures for the corresponding period of 2023.

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (UNAUDITED)

For the three months ended 31 March 2024

	For the three months ended	
	31 March	
	2024	2023
	(Unaudited)	(Unaudited)
	RMB’000	RMB’000
Revenue	280,329	299,718
Cost of Sales	<u>(171,805)</u>	<u>(158,915)</u>
Gross profit	108,524	140,803
Other revenue	2,507	3,167
Other net income	23	314
Selling and distribution expenses	(50,760)	(87,457)
Administrative expenses	(22,464)	(22,959)
Other operating expenses	<u>(11,862)</u>	<u>(9,955)</u>
Profit from operations	25,968	23,913

**CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER
COMPREHENSIVE INCOME (UNAUDITED)**

For the three months ended 31 March 2024

	For the three months ended	
	31 March	
	2024	2023
	(Unaudited)	(Unaudited)
	RMB'000	RMB'000
Finance costs	<u>(1,074)</u>	<u>(1,604)</u>
Profit before taxation	24,894	22,309
Income tax expense	<u>(5,009)</u>	<u>(3,111)</u>
Profit and total comprehensive income for the period	<u>19,885</u>	<u>19,198</u>
Profit and total comprehensive income for the period attributable to:		
Owners of the Company	19,300	16,264
Non-controlling interests	<u>585</u>	<u>2,934</u>
Earnings per share for profit attributable to the owners of the Company during the period		
Basic and diluted	<u>RMB1.15 cents</u>	<u>RMB0.97 cents</u>

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (UNAUDITED)*For the three months ended 31 March 2024*

	Attributable to owners of the Company							Total equity
	Share capital	Share premium	Capital reserve	Statutory reserve fund	Retained earnings	Sub-total	Non-controlling interests	
	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>
At 1 January 2023 (Audited)	167,800	554,844	(188,494)	51,082	298,810	884,042	121,262	1,005,304
Change in equity for 2023								
Profit and other comprehensive income for the period	—	—	—	—	16,264	16,264	2,934	19,198
At 31 March 2023 (Unaudited)	167,800	554,844	(188,494)	51,082	315,074	900,306	124,196	1,024,502
At 1 January 2024 (Audited)	167,800	554,844	(188,494)	52,803	321,216	908,169	108,013	1,016,182
Change in equity for 2024								
Profit and other comprehensive income for the period	—	—	—	—	19,300	19,300	585	19,885
At 31 March 2024 (Unaudited)	167,800	554,844	(188,494)	52,803	340,516	927,469	108,598	1,036,067

By Order of the Board
Shenzhen Neptunus Interlong Bio-technique Company Limited*
Zhang Feng
Chairman

Shenzhen, the PRC, 27 May 2024

As at the date of this announcement, the executive Directors are Mr. Zhang Feng, Mr. Huang Jian Bo and Mr. Zhang Xiao Guang; the non-executive Directors are Mr. Zhang Yi Fei, Ms. Yu Lin and Mr. Jin Rui; and the independent non-executive Directors are Mr. Yick Wing Fat, Simon, Mr. Poon Ka Yeung and Mr. Zhang Jian Zhou.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of the Stock Exchange for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Company Announcements” page of the GEM website at www.hkgem.com for at least 7 days from its date of publication and on the Company’s website at www.interlong.com.

* For identification purpose only